WSJ Tech News Briefing · Monday, July 27, 2026

AstraZeneca on Track for 2030 Revenue Target Despite Trial Setback

AstraZeneca's CEO stated the company remains on track to meet its 2030 revenue targets, even after a recent pivotal trial missed a key mark. The CEO explained that the company's projections are adjusted for the expected failure of some drug candidates.

tickerAZNcompanyAstraZeneca

The tape

2 quotes

“And AstraZeneca says it's on track to hit its revenue target for 2030 after a pivotal trial missed a demurral mark earlier this month.”

Imani Moyeze

“The CEO of the UK drugmaker says that the company assumes from the outset that some of its drug candidates would fail, and that its target was based on sales forecast adjusted for that risk.”

Imani Moyeze

Heard on WSJ Tech News Briefing — “TNB Tech Minute: Nvidia’s $250 Billion Plan To Back Data Center Sends Shares Lower”, published Monday, July 27, 2026. Heardvine summarizes and quotes with attribution and timestamps, and links to the original everywhere.

All WSJ Tech News Briefing coverage →Original episode audio ↗Show RSS feed ↗

Transcribed via Gemini audio transcription · $0.00